Revalesio’s RNS60 Reduces Cardiac Damage in Pig Study of Heart Attacks
Date: November 14, 2011
Revalesio Corporation is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating the use of RNS60 may have beneficial effects on cardiac damage associated with heart attacks. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida.
Read More…